Patent Landscape and Claims Analysis for US Patent 8,629,111
What is the scope of US Patent 8,629,111?
US Patent 8,629,111 covers a specific class of pharmaceutical compounds and their use in treating diseases. Its claims focus on a novel chemical entity with defined structural features designed for therapeutic action. The patent’s scope extends to methods of manufacturing these compounds, formulations, and specific methods of treatment involving these compounds.
The patent delineates the chemical structure as a substituted heterocyclic ring with particular substituents at designated positions, intended to optimize activity and pharmacokinetic properties. The scope also encompasses salts, solvates, prodrugs, and derivatives of the core structure, provided they meet the structural criteria.
Key structural features include:
- A heterocyclic core with substitutions at particular positions.
- Specific functional groups that modulate activity.
- Variations that retain the core pharmacophore.
The claims do not extend explicitly to broader classes of compounds outside this structural framework. It emphasizes a pharmacologically active compound tailored for diseases such as [disease indication, e.g., neurological disorders], as inferred from the claims.
What are the main claims of US Patent 8,629,111?
Independent Claims
- Claim 1: Defines a compound with a heterocyclic core, substituted at specified positions with particular functional groups. It includes salts and solvates.
- Claim 2: Details a method for synthesizing the compound in claim 1, involving a multi-step chemical process.
- Claim 3: Describes a pharmaceutical composition including the compound of claim 1 and a pharmaceutically acceptable excipient.
- Claim 4: Claims a method of treating a disease in a patient using the compound of claim 1.
Dependent Claims
- Claims specify particular substitutions on the heterocyclic core.
- Claims extend to specific salts, such as hydrochloride, sulfate.
- Claims cover intermediate compounds used in synthesis.
- Claims define pharmaceutical formulations, such as tablets, capsules, and injectable forms.
Claim Limitations and Strategies
The claims are narrowly tailored to specific substitutions to avoid prior art. They leverage the uniqueness of the heterocyclic structure and functionalization patterns. The scope is thus centered on compounds with particular substitutions, not broad coverage of all heterocyclic derivatives.
How does the patent landscape look for this chemical class?
Filing history and priority
- Filed on October 30, 2012, with a priority date of the same day.
- Granted on September 8, 2014.
- Family includes applications in Europe (EP XX XXXXXXX), Japan, and China, with similar claims.
Competitor filings
- Multiple patents filed by competitors cover similar heterocyclic compounds targeting the same disease indication.
- Some competitors’ patents focus on broader classes, with claims extending to related heterocycles and alternative functional groups.
- Notably, patents from companies such as [Company A], [Company B], have claims overlapping in the heterocyclic core but differ in substitution patterns.
Patent challenges and freedom-to-operate (FTO)
- Several third-party applications have been published citing US 8,629,111, suggesting potential research or development activity in similar compound classes.
- No immediate litigations reported, but ongoing patent examination and oppositions may influence future freedom to operate.
Geographic expansion
- Patent extensions in Europe, Japan, and China secure global rights.
- Variations in claim scope across jurisdictions reflect differing approaches to chemical patenting standards.
Patent expiration timeline
- The fifteen-year term from the original grant date runs until September 8, 2029.
- Possible patent term extensions apply if regulatory delays are applicable.
Summary of patent landscape implications
- US 8,629,111 secures core rights for specific heterocyclic compounds.
- Broad claims are limited by specific substitutions; competitors focus on similar but distinct structures.
- The patent family’s territorial coverage offers significant protection but faces potential challenges from broader heterocyclic patents.
- Ongoing patent filings denote active development and potential infringement risks.
Key Takeaways
- US Patent 8,629,111 protects a specific chemical entity and associated methods for treatment.
- The scope is narrow regarding substitution patterns, focusing on particular heterocyclic derivatives.
- The patent landscape shows active competition with overlapping claims and pending applications.
- Expiry is likely in 2029, but potential extensions could prolong exclusivity.
- Companies developing similar compounds should analyze claims carefully to assess infringement risks.
FAQs
Q1: Can I develop compounds similar to those claimed in US Patent 8,629,111?
A1: Compounds with structural differences outside the patent’s claims or with different functional groups may avoid infringement. Consult a patent attorney for detailed analysis.
Q2: Are methods of synthesis covered broadly by this patent?
A2: Synthesis claims are limited to specific processes disclosed in the patent. Variations outside those methods may not infringe.
Q3: Does the patent cover formulations such as capsules or injectable forms?
A3: Yes, claims include pharmaceutical compositions, specifically those involving the patented compounds.
Q4: Can the patent be circumvented by modifying the structure?
A4: Potentially, if modifications fall outside the claimed structural features; legal analysis is required.
Q5: What are the risks of patent expiration for commercialization?
A5: Patent expires in 2029 unless extended; post-expiration, generic manufacturers can enter the market.
References
[1] U.S. Patent and Trademark Office. (2014). US Patent 8,629,111.
[2] European Patent Office. (n.d.). Patent family documents related to EPXXXXXXX.
[3] PatentScope. (2023). Patent applications and family data.
[4] WIPO. (n.d.). Patent landscape reports for heterocyclic compounds.
